The study, already available in US and EU5, delivers a comprehensive picture of the laboratories involved in cancer biomarker testing.
As a key component of Ipsos’ Oncology Molecular Diagnostics Portfolio, the Lab Mapping Study collects a wide range of information from Lab Directors. The resulting data enables subscribers to:
- identify the type, structure and workforce of the laboratories;
- gather details around testing volume and tissue flow;
- quantify the volume of testing carried out by cancer type and methodology of biomarker testing.
Commented Pieter De Richter, Head of Ipsos Healthcare’s Real World Evidence Portfolio in Asia Pacific, Middle East & North Africa:
“The Molecular Diagnostics landscape in Oncology is evolving rapidly. The Lab Mapping Study allows pharmaceutical companies and molecular diagnostics manufacturers to better understand the workflow between the various types of labs involved with biomarker testing in each country, and how they are adapting to the changes in the marketplace. Combined with the Molecular Diagnostics Monitor, which focuses on Oncologist and Pathologist perceptions and behaviour, the Lab Mapping Study provides a holistic, multi-stakeholder view of cancer biomarker testing.”
Ipsos Healthcare Launches Syndicated Pan-Cancer Testing Monitor in Australia
Ipsos Healthcare has announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market. The PCTM, which has been running in the US since 2016, measures and tracks the usage of pan-cancer tests, which are designed to test for a wide range of cancer types to help doctors make more informed treatment decisions.